R&D Parkinson’s disease: Transitioning from symptom control to d... The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.
News Parkinson's charity partners Biognosys on biomarker project A new R&D project will try to develop assays for LRRK2, a biomarker linked to Parkinson's that has emerged as a major drug target in the disease.
News Diagnostics lag is holding back new therapies, says study Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
News Could Alzheimer's be predicted with a finger-prick test? An international trial has started to see if a simple finger-prick blood test could predict Alzheimer's before symptoms start.
News New guidance covers AI-based biomarkers for cancer care ESMO guidance on the validation and clinical use of AI-based biomarkers in oncology aims to strike a balance between caution and over-reliance.
News UK start-up Procyon has pancreatic cancer test in its sights Procyon is hoping to launch a diagnostic test next year that will be able to detect people at risk of pancreatic cancer from a urine sample.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.